# 510(k) Summary

<table><tr><td>510(k) Owner:</td><td>Alfa Wassermann Diagnostic Technologies, LLC 4 Henderson Drive West Caldwell, NJ 07006 Contact: HKatz@AlfaWassermannUS.com Hyman Katz, Ph.D. Phone: 973-852-0158 Fax: 973-852-0237</td><td></td><td>OCT 0 2 2013</td></tr><tr><td>Date Summary Prepared:</td><td colspan="3">September 26, 2013 Trade Name: ACE Direct Total Iron-Binding Capacity (TIBC)</td></tr><tr><td>Device:</td><td>Classification: Common/Classification Name:</td><td>Reagent Class 1 (21 C.F.R. § 862.1415) Product Code JMO</td><td>Direct Total Iron-Binding Capacity (TIBC)</td></tr><tr><td rowspan="7"></td><td>Trade Name:</td><td colspan="2">ACE Total Iron Reagent</td></tr><tr><td>Classification: Common/Classification Name:</td><td>Class 1 Photometric Method, Iron (Non-Heme)</td><td></td></tr><tr><td></td><td>(21 C.F.R. § 862.1410) Product Code JIY</td><td></td></tr><tr><td>Trade Name:</td><td>ACE LDH-L Reagent</td><td></td></tr><tr><td>Classification:</td><td>Class 2</td><td></td></tr><tr><td>Common/Classification Name:</td><td>Dehydrogenase (21 C. F.R. § 862.1440) Product Code CFJ</td><td>NAD Reduction/NADH Oxidation, Lactate</td></tr></table>

<table><tr><td>Predicate Devices:</td><td>Manufacturer for reagent system predicates: Alfa Wassermann ACE Clinical Chemistry System and ACE Reagents (K930104, K944911, K931786)</td></tr><tr><td>Device Descriptions:</td><td>In the ACE Direct Total Iron-Binding Capacity (TIBC) Reagent assay, Direct TIBC Color Reagent, an acidic buffer containing an iron-binding dye and ferric chloride, is added to the serum sample. The low pH of Direct TIBC Color Reagent releases iron from transferrin. The iron then forms a colored complex with the dye. The colored complex at the end of the first step represents both the serum iron and excess iron already present in Direct TIBC Color Reagent. Direct TIBC Buffer, a neutral buffer, is then added, shifting the pH and resulting in a large increase in the affinity of transferrin for iron. The serum transferrin rapidly binds the iron by abstracting it from the dye-iron complex. The observed decrease in absorbance of the colored dye-iron complex is directly proportional to the total iron-binding capacity of the serum sample. The absorbance is measured at</td></tr><tr><td></td><td>In the ACE Total Iron Reagent assay, transferrin-bound iron in serum is released at an acidic pH and reduced from ferric to ferrous ions. These ions react with ferrozine to form a violet colored complex, which is measured bichromatically at 554 nm/692 nm. The intensity of color produced is directly proportional to the serum iron concentration. In the ACE LDH-L Reagent assay, lactate dehydrogenase catalyzes the conversion of L- lactate to pyruvate. Nicotinamide adenine dinucleotide (NAD*) acts as an acceptor for the hydrogen ions released from the L-lactate and is converted to reduced nicotinamide adenine dinucleotide (NADH). NADH absorbs strongly at 340 nm whereas NAD* does not. Therefore, the rate of conversion of NAD* to NADH can be determined by monitoring the increase in absorbance bichromatically at 340 nm/647 nm. This rate of</td></tr><tr><td>iron-containing pigments, hemosiderin and hemofuscin, and characterized by pigmentation of the skin), and chronic renal disease. This test is intended for. use in clinical laboratories and physician office laboratories. For in vitro diagnostic use only.</td><td>The ACE Direct Total Iron-Binding (TIBC) Reagent is intended for the quantitative determination of total iron-binding capacity in serum using the ACE Alera Clinical Chemistry System. Iron-binding capacity measurements are used in the diagnosis and treatment of anemia. This test is intended for use in clinical laboratories and physician office laboratories. For in vitro diagnostic use only. The ACE Total Iron Reagent is intended for the quantitative determination of iron in serum using the ACE Alera Clinical Chemistry System. Iron (non-heme) measurements are used in the diagnosis and treatment of diseases such as iron deficiency anemia, hemochromatosis (a disease associated with widespread deposit in the tissues of two</td></tr><tr><td>Technological</td><td>The ACE LDH-L Reagent is intended for the quantitative determination of lactate dehydrogenase activity in serum using the ACE Alera Clinical Chemistry System. Lactate dehydrogenase measurements are used in the diagnosis and treatment of liver diseases such as acute viral hepatitis, cirrhosis, and metastatic carcinoma of the liver, cardiac diseases such as myocardial infarction and tumors of the lung or kidneys. This test is intended for use in clinical laboratories and physician office laboratories. For in vitro diagnostic use only.</td></tr><tr><td rowspan="3">Characteristics:</td><td>The ACE Direct Total Iron-Binding Capacity (TIBC) Reagent is composed of two reagent bottles (Direct TIBC Color Reagent and Direct TIBC Buffer). The Direct TIBC Color Reagent (R1) contains: Chromazurol B, Cetrimide, ferric chloride and acetate buffer. The Direct TIBC Buffer (R2) contains: sodium bicarbonate buffer.</td></tr><tr><td>The ACE Total Iron Reagent is composed of two reagent bottles (Buffer and Color Reagent). The Buffer (R1) contains: hydroxylamine hydrochloride, acetate buffer (pH 4.5) and surfactant. The Color Reagent (R2) contains: ferrozine and hydroxylamine hydrochloride.</td></tr><tr><td>The ACE LDH-L Reagent is composed of two reagent bottles (Substrate and Coenzyme Reagent). The reagents contain L-lactic acid and nicotinamide adenine dinucleotide.</td></tr></table>

# Comparison of similarities and differences with predicate device

Device Comparison with Predicate   
ACE Direct Total Iron-Binding Capacity (TIBC) Reagent   

<table><tr><td rowspan=1 colspan=1>ACE Direct TIBCReagent      a</td><td rowspan=1 colspan=1>Candidate Device         *3}$$\\}$$a</td><td rowspan=1 colspan=1>3  Predicate Device$        k930104    (ACE Direct TIBC Reagent)</td></tr><tr><td rowspan=1 colspan=1>Intended Use/Indications for Use</td><td rowspan=1 colspan=1>The ACE Direct Total Iron-BindingCapacity (TIBC) Reagent is intended forthe quantitative determination of totaliron-binding capacity in serum using theACE Alera Clinical Chemistry System.Iron-binding capacity measurements areused in the diagnosis and treatment ofanemia. This test is intended for use inclinical laboratories and physicianoffice laboratories. For in vitrodiagnostic use only.</td><td rowspan=1 colspan=1>The ACE Direct Total Iron-Binding Capacity (TIBC)Reagent is intended for thequantitative determination oftotal iron-binding capacity inserum using the ACEClinical Chemistry System.Iron-binding capacitymeasurements are used in the .diagnosis and treatment ofanemia. This test is intendedfor use in clinicallaboratories. For in vitrodiagnostic use only.</td></tr><tr><td rowspan=1 colspan=1>Method</td><td rowspan=1 colspan=1>Photometric</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibration Stability</td><td rowspan=1 colspan=1>30 days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>On Board Stability</td><td rowspan=1 colspan=1>30 days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Volume</td><td rowspan=1 colspan=1>16 μL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reaction Volume</td><td rowspan=1 colspan=1>291 μL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Expected values</td><td rowspan=1 colspan=1>250-425 μg/dL</td><td rowspan=1 colspan=1>250-450 μg/dL</td></tr><tr><td rowspan=1 colspan=1>Measuring range</td><td rowspan=1 colspan=1>52-700 μg/dL</td><td rowspan=1 colspan=1>From the lowest calibratorconcentration to 700 μg/dL</td></tr><tr><td rowspan=1 colspan=1>Sample Stability</td><td rowspan=1 colspan=1>Separated from cells, serum TIBC isstable for 4 days at 18-26°C and 1week at 2-8°C.</td><td rowspan=1 colspan=1>Same</td></tr></table>

# ACE Total Iron Reagent

<table><tr><td colspan="1" rowspan="1">ACE Total IronReagent</td><td colspan="1" rowspan="1">Candidate DeviceI</td><td colspan="1" rowspan="1">Predicate Device:k944911: (ACE Total Iron Reagent)</td></tr><tr><td colspan="1" rowspan="1">IntendedUse/Indications forUse</td><td colspan="1" rowspan="1">The ACE Total Iron Reagent is intendedfor the quantitative determination of ironin serum using the ACE Alera ClinicalChemistry System. Iron (non-heme)measurements are used in the diagnosisand treatment of diseases such as irondeficiency anemia, hemochromatosis (adisease associated with widespreaddeposit in the tissues of two iron-containing pigments, hemosiderin andhemofuscin, and characterized bypigmentation of the skin), and chronicrenal disease. This test is intended for usein clinical laboratories and physicianoffice laboratories. For in vitrodiagnostic use only.</td><td colspan="1" rowspan="1">The ACE Total Iron Reagentis intended for thequantitative determination ofiron in serum using the ACEClinical Chemistry System.Iron (non-heme)measurements are used in thediagnosis and treatment ofdiseases such as irondeficiency anemia,hemochromatosis (a diseaseassociated with widespreaddeposit in the tissues of twoiron-containing pigments,hemosiderin and hemofuscin,and characterized bypigmentation of the skin),and chronic renal disease.This test is intended for usein clinical laboratories. Forin vitro diagnostic use only.</td></tr><tr><td colspan="1" rowspan="1">Method</td><td colspan="1" rowspan="1">Photometric</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Calibration Stability</td><td colspan="1" rowspan="1">30 days</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">On Board Stability</td><td colspan="1" rowspan="1">30 days</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample Type</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample Volume</td><td colspan="1" rowspan="1">50 μL</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reaction Volume</td><td colspan="1" rowspan="1">335 μL</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Expected values</td><td colspan="1" rowspan="1">Male: 65-175 μg/dLFemale: 50-170 μg/dL</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Measuring range</td><td colspan="1" rowspan="1">9.15-600 μg/dL</td><td colspan="1" rowspan="1">2-600 μg/dL</td></tr><tr><td colspan="1" rowspan="1">Sample Stability</td><td colspan="1" rowspan="1">Separated from cells, serum iron is stablefor 7 days at room temperature (20-25°C),3 weeks at 4-8°C and up to 1 year at-20°C.</td><td colspan="1" rowspan="1">Separated from cells, serumiron is stable for 4 days atroom temperature (15-30°C)and 7 days at 2-8°C.</td></tr><tr><td colspan="1" rowspan="1">ACE LDH-L Reagent</td><td colspan="1" rowspan="1">Candidate Device</td><td colspan="1" rowspan="1">Predicate Devicek931786(ACE LDH-L Reagent)</td></tr><tr><td colspan="1" rowspan="1">IntendedUse/Indicationsfor Use</td><td colspan="1" rowspan="1">The ACE LDH-L Reagent isintended for the quantitativedetermination of lactatedehydrogenase activity in serumusing the ACE Alera ClinicalChemistry System. Lactatedehydrogenase measurements areused in the diagnosis andtreatment of liver diseases such asacute viral hepatitis, cirrhosis, andmetastatic carcinoma of the liver,cardiac diseases such asmyocardial infarction and tumorsof the lung or kidneys. This test isintended for use in clinicallaboratories and physicianoffice laboratories. For in vitrodiagnostic use only.</td><td colspan="1" rowspan="1">The ACE LDH-L Reagent isintended for the quantitativedetermination of lactatedehydrogenase activity inserum using the ACE ClinicalChemistry System. Lactatedehydrogenase measurementsare used in the diagnosis andtreatment of liver diseases suchas acute viral hepatitis,cirrhosis, and metastaticcarcinoma of the liver, cardiacdiseases such as myocardialinfarction and tumors of thelung or kidneys. This test isintended for use in clinicallaboratories. For in vitrodiagnostic use only.</td></tr><tr><td colspan="1" rowspan="1">Method</td><td colspan="1" rowspan="1">Photometric</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Calibration Stability</td><td colspan="1" rowspan="1">Not a calibrated test</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">On Board Stability</td><td colspan="1" rowspan="1">30 days</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample Type</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample Volume</td><td colspan="1" rowspan="1">5 μL</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reaction Volume</td><td colspan="1" rowspan="1">170 μL</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Expected values</td><td colspan="1" rowspan="1">100-190 U/L</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Measuring range</td><td colspan="1" rowspan="1">18-850 U/L</td><td colspan="1" rowspan="1">17-850 U/L</td></tr><tr><td colspan="1" rowspan="1">Sample Stability</td><td colspan="1" rowspan="1">Separated from cells, LDH activityis stable for 7 days at 20-25°C, 4days at 4-8°C and 6 weeks at -20°C.Loss of activity after freezing hasalso been noted.</td><td colspan="1" rowspan="1">Separated from cells, LDHactivity is stable for 3 days atboth 2-8°C and roomtemperature. Loss of activityafter freezing has also beennoted.</td></tr></table>

Performance Data:   
Reportable   
Range

# Performance data for the Alfa Wassermann ACE Reagents on the Alfa Wassermann ACE Alera Clinical Chemistry System

Detection Limits - ACE Alera Clinical Chemistry System

<table><tr><td rowspan=1 colspan=1>EMPY</td><td rowspan=1 colspan=1>TIBC</td><td rowspan=1 colspan=1>Iron</td><td rowspan=1 colspan=1>LDH-L   33</td></tr><tr><td rowspan=1 colspan=1>LoB</td><td rowspan=1 colspan=1>11 μg/dL</td><td rowspan=1 colspan=1>0 μg/dL</td><td rowspan=1 colspan=1>11 U/L</td></tr><tr><td rowspan=1 colspan=1>LoD</td><td rowspan=1 colspan=1>24 μg/dL</td><td rowspan=1 colspan=1>1 μg/dL</td><td rowspan=1 colspan=1>18 U/L</td></tr><tr><td rowspan=1 colspan=1>LoQ</td><td rowspan=1 colspan=1>52 μg/dL</td><td rowspan=1 colspan=1>9.15 μg/dL</td><td rowspan=1 colspan=1>18 U/L</td></tr></table>

# Linearity - ACE Alera Clinical Chemistry System

<table><tr><td rowspan=1 colspan=1>. Reagent</td><td rowspan=1 colspan=1>Low LevelTested</td><td rowspan=1 colspan=1>High Level.. Tested</td><td rowspan=1 colspan=1>Linear to:</td><td rowspan=1 colspan=1>Linear Regressionequation</td></tr><tr><td rowspan=1 colspan=1>TIBC</td><td rowspan=1 colspan=1>34 μg/dL</td><td rowspan=1 colspan=1>740 μg/dL</td><td rowspan=1 colspan=1>700 μg/dL</td><td rowspan=1 colspan=1>y = 1.020x + 3.1$^{ }=0.9981</td></tr><tr><td rowspan=1 colspan=1>Iron</td><td rowspan=1 colspan=1>6 μg/dL</td><td rowspan=1 colspan=1>666 μg/dL</td><td rowspan=1 colspan=1>600 μg/dL</td><td rowspan=1 colspan=1>y= 1.030x + 1.9$^{}= 0.9986</td></tr><tr><td rowspan=1 colspan=1>LDH-L</td><td rowspan=1 colspan=1>8 U/L</td><td rowspan=1 colspan=1>895 U/L</td><td rowspan=1 colspan=1>850 U/L</td><td rowspan=1 colspan=1>y=1.050x -0.7^{2}= 0.9981</td></tr></table>

<table><tr><td>Performance Data:</td><td rowspan="3"></td></tr><tr><td>Interferences</td></tr><tr><td></td></tr></table>

# Interferences - ACE Alera Clinical Chemistry System

<table><tr><td rowspan=2 colspan=1>Interferent</td><td rowspan=1 colspan=3>No Significant Interference at or below:</td></tr><tr><td rowspan=1 colspan=1>TIBCi</td><td rowspan=1 colspan=1>Iron*</td><td rowspan=1 colspan=1>LDH-L2</td></tr><tr><td rowspan=1 colspan=1>Icterus</td><td rowspan=1 colspan=1>59 mg/dL</td><td rowspan=1 colspan=1>59 mg/dL</td><td rowspan=1 colspan=1>50 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Hemolysis</td><td rowspan=1 colspan=1>188 mg/dL*</td><td rowspan=1 colspan=1>125 mg/dL*</td><td rowspan=1 colspan=1>&lt;31 mg/dL*</td></tr><tr><td rowspan=1 colspan=1>Lipemia</td><td rowspan=1 colspan=1>1000 mg/dL</td><td rowspan=1 colspan=1>125 mg/dL</td><td rowspan=1 colspan=1>1000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Ascorbic Acid</td><td rowspan=1 colspan=1>3 mg/dL</td><td rowspan=1 colspan=1>6 mg/dL</td><td rowspan=1 colspan=1>6 mg/dL</td></tr></table>

\* Do not use hemolyzed samples.

Performance Data: Precision - In-House

# Precision - ACE Alera Clinical Chemistry System

<table><tr><td rowspan=2 colspan=2>&#x27; oi  ;1;      ACE Alera     j    =E</td><td rowspan=1 colspan=3>7   a           Precision (SD, %CV)                      *5.$*</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>5  Within-Run</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>TIBCμg/dL</td><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>217</td><td rowspan=1 colspan=1>4.1, 1.9%</td><td rowspan=1 colspan=1>6.7, 3.1%</td></tr><tr><td rowspan=1 colspan=1>Mid</td><td rowspan=1 colspan=1>270•</td><td rowspan=1 colspan=1>3.7, 1.4%</td><td rowspan=1 colspan=1>7.1, 2.6%</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>310</td><td rowspan=1 colspan=1>5.0, 1.6%</td><td rowspan=1 colspan=1>8.6, 2.8%</td></tr><tr><td rowspan=3 colspan=1>Ironμg/dL</td><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>3.2, 5.2%</td><td rowspan=1 colspan=1>4.6, 7.3%</td></tr><tr><td rowspan=1 colspan=1>Mid</td><td rowspan=1 colspan=1>145</td><td rowspan=1 colspan=1>2.2, 1.5%</td><td rowspan=1 colspan=1>4.2, 2.9%</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>226</td><td rowspan=1 colspan=1>4.1, 1.8%</td><td rowspan=1 colspan=1>5.0, 2.2%</td></tr><tr><td rowspan=4 colspan=1>LDH-LU/L</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>77</td><td rowspan=1 colspan=1>3.8, 4.9%</td><td rowspan=1 colspan=1>4.2, 5.5%</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>119</td><td rowspan=1 colspan=1>5.1, 4.3%</td><td rowspan=1 colspan=1>5.2, 4.3%</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>4.5, 1.7%</td><td rowspan=1 colspan=1>5.8, 2.1%</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>651</td><td rowspan=1 colspan=1>12.6, 1.9%</td><td rowspan=1 colspan=1>13.5, 2.1%</td></tr></table>

In-House ACE $( \mathbf { x } )$ vs. In-House ACE Alera (y)   

<table><tr><td rowspan=1 colspan=1>P&lt;</td><td rowspan=1 colspan=1>•TIBC4.{•</td><td rowspan=1 colspan=1>Iron</td><td rowspan=1 colspan=1>$}$LDH-L</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>58</td></tr><tr><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>59 to 676 μg/dL</td><td rowspan=1 colspan=1>13 to 549 μg/dL</td><td rowspan=1 colspan=1>20 to 799 U/L</td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>0.987</td><td rowspan=1 colspan=1>0.993</td><td rowspan=1 colspan=1>0.997</td></tr><tr><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>-3.6</td></tr><tr><td rowspan=1 colspan=1>CorrelationCoefficient</td><td rowspan=1 colspan=1>0.9960</td><td rowspan=1 colspan=1>0.9995</td><td rowspan=1 colspan=1>0.9991</td></tr><tr><td rowspan=1 colspan=1>Std. Error</td><td rowspan=1 colspan=1>9.2</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>6.8</td></tr><tr><td rowspan=1 colspan=1>CI Slope</td><td rowspan=1 colspan=1>0.962 to 1.013</td><td rowspan=1 colspan=1>0.984 to 1.003</td><td rowspan=1 colspan=1>0.985 to 1.008</td></tr><tr><td rowspan=1 colspan=1>CI Intercept</td><td rowspan=1 colspan=1>-7.2 to 14.4</td><td rowspan=1 colspan=1>-0.6 to 2.3</td><td rowspan=1 colspan=1>-6.1 to -1.1</td></tr></table>

<table><tr><td>Performance Data: Method Comparison In-House</td><td rowspan="3"></td></tr><tr><td></td></tr><tr><td></td></tr></table>

Data:

PrecisionPOL

<table><tr><td rowspan=2 colspan=2>Direct TIBCn20</td><td rowspan=1 colspan=3>ACE Result</td><td rowspan=1 colspan=3>ACE Alera Result</td></tr><tr><td rowspan=2 colspan=1>,*Mean</td><td rowspan=1 colspan=2>μg/dL SD, %CV</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>..μg/dL SD, %CV</td></tr><tr><td rowspan=1 colspan=1>&lt;  Lab</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>336</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>5.5</td><td rowspan=2 colspan=1>330</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>5.8</td></tr><tr><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>1.8%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>290</td><td rowspan=1 colspan=1>10.8</td><td rowspan=1 colspan=1>15.6</td><td rowspan=2 colspan=1>284</td><td rowspan=1 colspan=1>8.3</td><td rowspan=1 colspan=1>9.6</td></tr><tr><td rowspan=1 colspan=1>3.7%</td><td rowspan=1 colspan=1>5.4%</td><td rowspan=1 colspan=1>2.9%</td><td rowspan=1 colspan=1>3.4%</td></tr><tr><td rowspan=2 colspan=1>POL 2.</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>275</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>11.4</td><td rowspan=2 colspan=1>259</td><td rowspan=1 colspan=1>5.6</td><td rowspan=1 colspan=1>8.5</td></tr><tr><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>4.1%</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>3.3%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>295</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>5.5</td><td rowspan=2 colspan=1>276</td><td rowspan=1 colspan=1>9.1</td><td rowspan=1 colspan=1>16.7</td></tr><tr><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>3.3%</td><td rowspan=1 colspan=1>6.0%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>′</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>&#x27;*</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>"</td><td rowspan=1 colspan=1>…</td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>455</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>8.1</td><td rowspan=2 colspan=1>450</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1>6.8</td></tr><tr><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>1.5%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>452</td><td rowspan=1 colspan=1>10.2</td><td rowspan=1 colspan=1>10.4</td><td rowspan=2 colspan=1>464</td><td rowspan=1 colspan=1>6.3</td><td rowspan=1 colspan=1>6.6</td></tr><tr><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>1.4%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>442</td><td rowspan=1 colspan=1>5.9</td><td rowspan=1 colspan=1>12.5</td><td rowspan=2 colspan=1>444</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>5.4</td></tr><tr><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>2.8%</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>1.2%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>465</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>5.3</td><td rowspan=2 colspan=1>453</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>15.5</td></tr><tr><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>0.7%</td><td rowspan=1 colspan=1>3.4%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>^ s</td><td rowspan=1 colspan=1>$</td><td rowspan=1 colspan=1>$frac{}$;&#x27;in*_</td><td rowspan=1 colspan=1>;        : ·</td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>539</td><td rowspan=1 colspan=1>9.8</td><td rowspan=1 colspan=1>12.8</td><td rowspan=2 colspan=1>530</td><td rowspan=1 colspan=1>9.4</td><td rowspan=1 colspan=1>10.8</td></tr><tr><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>2.0%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>531</td><td rowspan=1 colspan=1>17.1</td><td rowspan=1 colspan=1>20.4</td><td rowspan=2 colspan=1>544</td><td rowspan=1 colspan=1>8.2</td><td rowspan=1 colspan=1>8.3</td></tr><tr><td rowspan=1 colspan=1>3.2%</td><td rowspan=1 colspan=1>3.8%</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>1.5%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>530</td><td rowspan=1 colspan=1>7.4</td><td rowspan=1 colspan=1>14.1</td><td rowspan=2 colspan=1>520</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>9.0</td></tr><tr><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>1.7%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>551</td><td rowspan=1 colspan=1>4.6</td><td rowspan=1 colspan=1>5.9</td><td rowspan=2 colspan=1>533</td><td rowspan=1 colspan=1>12.6</td><td rowspan=1 colspan=1>20.2</td></tr><tr><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>3.8%</td></tr></table>

Performance Data: Precision - POL   
POL - Precision for ACE and ACE Alera Clinical Chemistry Systems   

<table><tr><td rowspan=2 colspan=2>&#x27;5   Total Iron $3} }$n=20I</td><td rowspan=1 colspan=3>ACE Result</td><td rowspan=1 colspan=3>:• ACE Alera Result +     -</td></tr><tr><td rowspan=2 colspan=1>Mean</td><td rowspan=1 colspan=2>μ/dL SD, %CV</td><td rowspan=2 colspan=1>Mean</td><td rowspan=1 colspan=2>μg/dL SD, %CV</td></tr><tr><td rowspan=1 colspan=1>Lab</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>117</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>2.6</td><td rowspan=2 colspan=1>119</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>2.5</td></tr><tr><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>2.1%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>120</td><td rowspan=1 colspan=1>6.4</td><td rowspan=1 colspan=1>6.9</td><td rowspan=2 colspan=1>119</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>3.2</td></tr><tr><td rowspan=1 colspan=1>5.4%</td><td rowspan=1 colspan=1>5.8%</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>2.7%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>120</td><td rowspan=1 colspan=1>6.3</td><td rowspan=1 colspan=1>6.6</td><td rowspan=2 colspan=1>122</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>3.1</td></tr><tr><td rowspan=1 colspan=1>5.3%</td><td rowspan=1 colspan=1>5.5%</td><td rowspan=1 colspan=1>2.6%</td><td rowspan=1 colspan=1>2.6%</td></tr><tr><td rowspan=2 colspan=1>POL3</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>121</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>4.4</td><td rowspan=2 colspan=1>116</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>3.4</td></tr><tr><td rowspan=1 colspan=1>3.7%</td><td rowspan=1 colspan=1>3.7%</td><td rowspan=1 colspan=1>2.8%</td><td rowspan=1 colspan=1>3.0%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>:      &#x27;</td><td rowspan=1 colspan=1>*: yγ*</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>:&quot;$</td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>223</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>5.6</td><td rowspan=2 colspan=1>222</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>5.1</td></tr><tr><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>2.3%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>227</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>3.9</td><td rowspan=2 colspan=1>229</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>2.5</td></tr><tr><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>1.1%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>227</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>5.1</td><td rowspan=2 colspan=1>235</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>2.4</td></tr><tr><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>1.0%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>225</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>1.9</td><td rowspan=2 colspan=1>229</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>3.9</td></tr><tr><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>1.7%</td></tr><tr><td rowspan=1 colspan=1>:        •;u</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>. : </td><td rowspan=1 colspan=1>:&#x27;</td><td rowspan=1 colspan=1>.</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>416</td><td rowspan=1 colspan=1>8.7</td><td rowspan=1 colspan=1>9.1</td><td rowspan=2 colspan=1>412</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>5.7</td></tr><tr><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>1.4%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>420</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>5.6</td><td rowspan=2 colspan=1>424</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>4.6</td></tr><tr><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>1.1%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>423</td><td rowspan=1 colspan=1>6.6</td><td rowspan=1 colspan=1>9.3</td><td rowspan=2 colspan=1>435</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>5.3</td></tr><tr><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>0.5%</td><td rowspan=1 colspan=1>1.2%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>422</td><td rowspan=1 colspan=1>5.6</td><td rowspan=1 colspan=1>6.0</td><td rowspan=2 colspan=1>428</td><td rowspan=1 colspan=1>11.1</td><td rowspan=1 colspan=1>11.1</td></tr><tr><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>2.6%</td><td rowspan=1 colspan=1>2.6%</td></tr></table>

Performance Data: PrecisionPOL   

<table><tr><td rowspan=2 colspan=2>LDH-Ln=20</td><td rowspan=1 colspan=3>ACE Result</td><td rowspan=1 colspan=3>ACE Alera Result</td></tr><tr><td rowspan=2 colspan=1>· &#x27;Mean</td><td rowspan=1 colspan=2>U/L SD, %CV</td><td rowspan=2 colspan=1>$\_{$Mean</td><td rowspan=1 colspan=2>*.  U/L SD, %CV     :x:</td></tr><tr><td rowspan=1 colspan=1>Lab</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>. Total</td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>121</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>4.3</td><td rowspan=2 colspan=1>118</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>5.7</td></tr><tr><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>3.6%</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>4.8%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>113</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>5.4</td><td rowspan=2 colspan=1>116</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>4.9</td></tr><tr><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>4.8%</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>4.3%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>114</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>6.4</td><td rowspan=2 colspan=1>118</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>5.1</td></tr><tr><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>5.6%</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>4.3%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>1</td><td rowspan=2 colspan=1>117</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>2.7</td><td rowspan=2 colspan=1>124</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>4.7</td></tr><tr><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>3.8%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>446</td><td rowspan=1 colspan=1>5.8</td><td rowspan=1 colspan=1>6.9</td><td rowspan=2 colspan=1>433</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>6.5</td></tr><tr><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>1.5%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>433</td><td rowspan=1 colspan=1>5.8</td><td rowspan=1 colspan=1>8.1</td><td rowspan=2 colspan=1>437</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>5.8</td></tr><tr><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>0.7%</td><td rowspan=1 colspan=1>1.3%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>433</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>5.7</td><td rowspan=2 colspan=1>449</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>5.2</td></tr><tr><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>1.2%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>2</td><td rowspan=2 colspan=1>437</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>5.2</td><td rowspan=2 colspan=1>446</td><td rowspan=1 colspan=1>5.8</td><td rowspan=1 colspan=1>6.6</td></tr><tr><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>1.5%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=2 colspan=1>In-House</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>715.</td><td rowspan=1 colspan=1>10.1</td><td rowspan=1 colspan=1>11.9</td><td rowspan=2 colspan=1>699</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>8.5</td></tr><tr><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>1.2%</td></tr><tr><td rowspan=2 colspan=1>POL 1</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>699</td><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>18.0</td><td rowspan=2 colspan=1>698</td><td rowspan=1 colspan=1>8.6</td><td rowspan=1 colspan=1>11.5</td></tr><tr><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>2.6%</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>1.6%</td></tr><tr><td rowspan=2 colspan=1>POL 2</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>698</td><td rowspan=1 colspan=1>12.7</td><td rowspan=1 colspan=1>12.7</td><td rowspan=2 colspan=1>726</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>10.0</td></tr><tr><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>1.4%</td></tr><tr><td rowspan=2 colspan=1>POL 3</td><td rowspan=2 colspan=1>3</td><td rowspan=2 colspan=1>697</td><td rowspan=1 colspan=1>7.6</td><td rowspan=1 colspan=1>8.8</td><td rowspan=2 colspan=1>716</td><td rowspan=1 colspan=1>14.3</td><td rowspan=1 colspan=1>16.9</td></tr><tr><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>2.4%</td></tr></table>

Method Comparison - POL on ACE   

<table><tr><td rowspan=1 colspan=5>POL - Method Comparison for ACE Clinical Chemistry System</td></tr><tr><td rowspan=1 colspan=1>en</td><td rowspan=1 colspan=1>°§s &lt;Statistic</td><td rowspan=1 colspan=1>In-House (x). vs.ACE POL 1 (y)</td><td rowspan=1 colspan=1>In-House (x)VS.ACE POL.2 (y)</td><td rowspan=1 colspan=1>In-House (x)vs.ACE POL 3 (y)</td></tr><tr><td rowspan=1 colspan=1>TIBC</td><td rowspan=1 colspan=1>nRangeRegressionCorrelationStd. Error Est.Cl SlopeCI Intercept</td><td rowspan=1 colspan=1>5059 to 676y = 0.979x + 4.30.99727.70.958 to 1.000-4.8 to 13.3</td><td rowspan=1 colspan=1>5059 to 676 .y = 0.974x + 8.70.99668.40.951 to 0.998-1.2 to 18.5</td><td rowspan=1 colspan=1>. 5059 to 676y = 1.006x - 1.40.99668.70.982 to 1.030-I1.6 to 8.8</td></tr><tr><td rowspan=1 colspan=1>Iron</td><td rowspan=1 colspan=1>nRangeRegressionCorrelationStd. Error Est.CI SlopeCl Intercept</td><td rowspan=1 colspan=1>4813 to 549y = 0.977x - 1.30.99905.00.964 to 0.990-3.3 to 0.6</td><td rowspan=1 colspan=1>4813 to 549y = 0.992x - 0.80.99943.80.982 to 1.003-2.3 to 0.7</td><td rowspan=1 colspan=1>4813 to 549y = 0.992x + 0.90.99943.80.982 to 1.002-0.6 to 2.4</td></tr><tr><td rowspan=1 colspan=1>LDH-L</td><td rowspan=1 colspan=1>nRangeRegressionCorrelationStd. Error Est.CI SlopeCI Intercept</td><td rowspan=1 colspan=1>5174 to 799y = 0.996x + 1.30.997910.60.978 to 1.014-3.0 to 5.6</td><td rowspan=1 colspan=1>5174 to 799y = 1.010x - 5.30.99897.70.996 to 1.023-8.5 to -2.2</td><td rowspan=1 colspan=1>5174 to 799y = 0.978x + 7.20.99897.60.964 to 0.9914.2 to 10.3</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Cl Intercept</td><td rowspan=1 colspan=1>-3.0 to 5.6</td><td rowspan=1 colspan=1>-8.5 to -2.2</td><td rowspan=1 colspan=1>4.2 to 10.3</td></tr></table>

<table><tr><td>Performance Data: Method</td><td rowspan="3">Comparison - POL on ACE</td></tr><tr><td>Alera</td></tr><tr><td>Conclusions:</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Reigent.</td><td rowspan=1 colspan=1>sturttatie"</td><td rowspan=1 colspan=1>In-House (x)· &#x27;vs.&#x27;ACE AleraPOL 1 (y)</td><td rowspan=1 colspan=1>In-House (x)vs.       :ACE AleraPOL 2 (y)</td><td rowspan=1 colspan=1>In-House (x)vs.    4.ACE AleraPOL.3 (y)</td></tr><tr><td rowspan=1 colspan=1>TIBC</td><td rowspan=1 colspan=1>nRangeRegressionCorrelationStd. Error Est.CI SlopeCI Intercept</td><td rowspan=1 colspan=1>5059 to 676y = 0.994x + 12.40.993412.00.961 to 1.027-1.7 to 26.5</td><td rowspan=1 colspan=1>5059 to 676y = 0.973x + 0.10.99549.80.946 to 1.001-11.4 to 11.6</td><td rowspan=1 colspan=1>5059 to 676y= 1.005x + 9.00.989815.10.963 to 1.047-8.7 to 26.6</td></tr><tr><td rowspan=1 colspan=1>Iron</td><td rowspan=1 colspan=1>nRangeRegressionCorrelationStd. Error Est.CI SlopeCI Intercept</td><td rowspan=1 colspan=1>4813 to 549y = 0.976x + 1.00.99865.90.960 to 0.991-1.4 to 3.3</td><td rowspan=1 colspan=1>4813 to 549y = 0.976x + 2.30.99816.80.959 to 0.994-0.4 to 5.0</td><td rowspan=1 colspan=1>4813 to 549y = 0.95 1x + 0.80.99668.90.927 to 0.974-2.7 to 4.4</td></tr><tr><td rowspan=1 colspan=1>LDH-L</td><td rowspan=1 colspan=1>nRangeRegressionCorrelationStd. Error Est.CI SlopeCI Intercept</td><td rowspan=1 colspan=1>5174 to 799y = 0.992x + 3.50.99868.80.977 to 1.008-0.1 to 7.1</td><td rowspan=1 colspan=1>5174 to 799y = 1.027x + 3.40.99898.11.013 to 1.0410.2 to 6.7</td><td rowspan=1 colspan=1>5174 to 799y =.1.010x + 2.50.99849.30.994 to 1.026-1.3 to 6.2</td></tr></table>

# October 2, 2013

Alfa Wassermann Diagnostic Technologies, LLC c/o Hyman Katz, Ph.D.   
4 Henderson Drive   
WEST CALDWELL NJ 07006

Re: K131975 Trade/Device Name: ACE LDH-L Reagent ACE Direct Total Iron-Binding Capacity (TIBC) Reagent ACE Total Iron Reagent Regulation Number: 21 CFR 862. 1440 Regulation Name: Lactate dehydrogenase test system Regulatory Class: I, exempt, meets limitations of exemption per 21 CFR 862.9 (c)(9) Product Code: CFJ, JMO, JIY Dated: August 30, 2013 Received: September 4, 2013

Dear Dr. Katz:

We have reviewed your Section 510(k) premarket notilication of intent to market the device referenced above and have determined the device is substantially cquivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug. ad Cosmetic Act (Act) that do nol requie approval f a premarkt aprovalapplicatin (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The gral controls provisions of the Actinclude requirements for annual registration, listing devices, good manufacturing practice, labcling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, thal device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can bc found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does nol mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statules and regulations administered by other Federal agencics. You must comply with all the Act's requirements, including. but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); imedical device reporting (reporting of medical device-related adverse cvents) (21 CFR 803): good manufacturing practicc requirements as sct forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act): 21 CFR 1000- 1050.

If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809), please contact the Division of Small Manufacturers, International and Consumer Assistance at is toll-free number (800) 638 2041or (301)796-7100 or at its Intemel adress http://www.fda.gov/MedicalDevices/ResourccsforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDeviccs/Safety/ReportaProblem/default,htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act rom the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/McdicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

# Carol C. Benson -Sfo

Courtney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics   
and Radiological Health   
Center for Devices and Radiological Health

# Indications for Use

510(k) Number : k131975

# Device Name:

# ACE Direct Total Iron-Binding Capacity (TIBC) Reagent

# Indications for Use:

The ACE Direct Total Iron-Binding Capacity (TIBC) Reagent is intended for the quantitative determination of total iron-binding capacity in serum using the ACE Alera Clinical Chemistry System. Iron-binding capacity measurements are used in the diagnosis and treatment of anemia. This test is intended for use in clinical laboratories and physician office laboratories. For in vitro diagnostic use only.

# Device Name:

ACE Total Iron Reagent

Indications for Use: The ACE Total Iron Reagent is intended for the quantitative determination of iron in serum using the ACE Alera Clinical Chemistry System. Iron (non-heme) measurements are used in the diagnosis and treatment of diseases such as iron deficiency anemia, hemochromatosis (a disease associated with widespread deposit in the tissues of two iron-containing pigments, hemosiderin and hemofuscin, and characterized by pigmentation of the skin), and chronic renal disease. This test is intended for use in clinical laboratories and physician office laboratories. For in vitro diagnostic use only.

AND/OR

Prescription Use X (21 CFR Part 801 Subpart D)

Over-The-Counter Use. (21 CFR Part 801 Subpart C)

# Page 2 of 2

# Indications for Use

510(k) Number : k131975

# Device Name:

ACE LDH-L Reagent

# Indications for Use:

The ACE LDH-L Reagent is intended for the quantitative determination of lactate dehydrogenase activity in serum using the ACE Alera Clinical Chemistry System. Lactate dehydrogenase measurements are used in the diagnosis and treatment of liver diseases such as acute viral hepatitis, cirrhosis, and metastatic carcinoma of the liver, cardiac diseases such as myocardial infarction and tumors of the lung or kidneys. This test is intended for use in clinical laboratories and physician office laboratories. For in vitro diagnostic use only.